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Abstract
Background: Direct Acting Antiviral (DAAs) drugs have a much lower burden of treatment and monitoring
requirements than regimens containing interferon and ribavirin, and a much higher efficacy in treating hepatitis C
(HCV). These characteristics mean that initiating treatment and obtaining a virological cure (Sustained Viral
response, SVR) on completion of treatment, in non-specialist environments should be feasible. We investigated the
English-language literature evaluating community and primary care-based pathways using DAAs to treat HCV
infection.
Methods: Databases (Cinahl; Embase; Medline; PsycINFO; PubMed) were searched for studies of treatment with
DAAs in non-specialist settings to achieve SVR. Relevant studies were identified including those containing a
comparison between a community and specialist services where available. A narrative synthesis and linked meta-
analysis were performed on suitable studies with a strength of evidence assessment (GRADE).
Results: Seventeen studies fulfilled the inclusion criteria: five from Australia; two from Canada; two from UK and
eight from USA. Seven studies demonstrated use of DAAs in primary care environments; four studies evaluated
integrated systems linking specialists with primary care providers; three studies evaluated services in locations
providing care to people who inject drugs; two studies evaluated delivery in pharmacies; and one evaluated
delivery through telemedicine. Sixteen studies recorded treatment uptake. Patient numbers varied from around 60
participants with pathway studies to several thousand in two large database studies. Most studies recruited less
than 500 patients. Five studies reported reduced SVR rates from an intention-to-treat analysis perspective because
of loss to follow-up before the final confirmatory SVR test. GRADE assessments were made for uptake of HCV
treatment (medium); completion of HCV treatment (low) and achievement of SVR at 12 weeks (medium).
Conclusion: Services sited in community settings are feasible and can deliver increased uptake of treatment. Such
clinics are able to demonstrate similar SVR rates to published studies and real-world clinics in secondary care.
Stronger study designs are needed to confirm the precision of effect size seen in current studies. Prospero:
CRD42017069873.
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Background
Of the 71 million persons infected with HCV, 5.6 million
(8%) currently inject drugs [1, 2]. The World Health
Organization (WHO) has defined global targets for HCV
diagnosis and treatment, which represents a major step
towards the aim of global elimination by 2030 [3].
However, rates of uptake of HCV testing, linkage to care
and treatment remain low across many countries [4]. Bar-
riers to accessing funded Direct Acting Antiviral (DAA)
drug treatment may be due to provider concerns regard-
ing co-morbidities, adherence, and side effects manage-
ment [5]. Social factors affecting treatment access have
been categorised as social stigma, housing, criminalisation,
health care providers’ attitudes and stigmatising practices,
and gender [6]. Individuals may prioritise other needs and
may be wary of the consequences of a diagnosis on their
circumstances; health systems may present complex and
rigid arrangements that must be navigated in order to ac-
cess care [7]. The stigma associated with both injecting
drug use and HCV infection is pervasive [8]. The concept
of the care cascade has focussed attention on the perform-
ance of different pathways and the attrition of patients
accessing testing, diagnosis, treatment and care [9].
It is common in many developed and developing coun-
tries, for specialist clinicians to provide HCV treatment,
often from hospital outpatient facilities [10]. Recently, pre-
scribing of DAAs has become common practice in many
countries [10]. Treatment of HCV with these medicines is
simple and well-tolerated [11]. The safety profile and high
efficacy of DAAs means that HCV treatment can be deliv-
ered by a range of non-specialist clinicians including
nurses, pharmacists and general practitioners, therefore
providing enhanced access to virological cure (SVR) [12].
The ease of transferring care to community and primary
care environments is assisted by the use of treatment regi-
mens that do not contain ribavirin or interferon [13]. Pro-
gress with implementing treatment pathways provided by
non-specialists in community and primary care environ-
ments has been identified as one of the key steps in the
elimination of HCV [14]. The World Health Organiza-
tion’s Guidelines for the care and treatment of persons
diagnosed with chronic hepatitis C virus infection pro-
mote simplified service delivery models: integration with
other services; decentralised services supported by task-
sharing; and community engagement, with the intention
of reducing stigma and increase uptake of treatment [14].
This review was undertaken to identify rates of treat-
ment uptake, treatment completion and achievement of
sustained viral response for adults infected with hepatitis
C using DAA-only treatment regimens in community and
primary care-based care pathways, evaluated by studies
using observational and experimental study designs. Stud-
ies that compared community-based treatment care path-
ways with specialist care were actively sought.
Methods
This systematic review was undertaken and reported ac-
cording to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement [15].
The methods of analysis and defined inclusion criteria
were specified in advance and documented in a study
protocol. The study was registered in PROSPERO
(CRD42017069873). The PICOS elements defined for
this review are set out in Table 1.
The rationale adopted in the design of the PICOS ele-
ments was intended to provide some answers to the
questions raised by the WHO Guidance and its recom-
mendations for simplified and decentralised treatment
delivery models, integrated with other services in com-
munity and primary-care environments [14]. Therefore a
population over 18 years old was selected, as being less
likely to have gained their infection through vertical
transmission. Co-infected individuals with other blood
borne virus infections were also excluded as their care
was likely to be more complex, requiring specialist ra-
ther than simplified care. Studies from prison popula-
tions were excluded since these individuals lived in
contained communities. Studies that utilised interferon
and ribavirin-based treatment regimes as the primary
intervention were also excluded, since monitoring and
patient management requirements, made simplified and
decentralised care less likely. Sustained viral response at
Table 1 Elements of the PICOS question defined for this review
Inclusion Exclusion
Population Age 18 years and over
Infected with hepatitis C
Age less than 18 years
Co-infection with Hepatitis B virus
Co-infection with HIV
Intervention Provision of hepatitis C treatment in any primary care and community environments
Treatment using any direct acting antiviral therapy
Care provider could be any health care provider
Hepatitis C treatment in prison populations
Treatment with ribavirin / interferon regimes
as the primary intervention
Comparison Care in any hospital or secondary care environment or no comparison group
Outcome Treatment uptake, treatment completion and SVR outcomes
Study
design
Observational studies, retrospective or prospective cohort studies, randomised trials;
conference abstracts; qualitative and mixed methods studies
Case studies; systematic reviews
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12 weeks (SVR12) was taken as a marker for virological
cure; failure to achieve SVR may be attributed to both
treatment failure and loss to follow-up [16]. Studies were
restricted to the English language since study resources
precluded any translation activities. Published studies
were utilised including conference abstracts, in order to
capture results from early studies when the first DAAs
were introduced into practice.
Search strategy
Published research was identified by formal searches of
five electronic databases (Cinahl, Embase, Medline, Psy-
cINFO, PubMed) from January 2013 to December 2017,
as well as Google Scholar. The last search was run on 11
December 2017. Search topics included “hepatitis C”,
“treatment” and “setting”. A comprehensive list of search
terms related to each of the search topics was used to
develop a search strategy for each electronic database.
Search strings were formulated by using a combination
of keywords and indexed subject headings (MeSH and
EMTREE terms). Primary care was defined using the
WHO accepted terminology that promotes Primary Care
as a key process in the health system: “it is first-contact,
accessible, continued, comprehensive and coordinated
care” [17] and community environments being the geo-
graphical locations where groups of people live.
The full search strategy is set out in Additional file 1. Ref-
erence lists of selected articles, citing articles and relevant
review articles retrieved during the initial search were hand-
searched and forward citation checks were undertaken to
identify any additional studies. Abstracts from the selected
scientific conferences were screened for review eligibility.
Study selection
Data retrieved through the study search strategy were
imported into EndNote X8 (Thomson Reuters, New York,
NY, USA) and any duplicates removed. Titles obtained
from the initial search strategy were screened and irrelevant
citations were removed. Abstracts were then assessed using
the inclusion and exclusion criteria by two reviewers inde-
pendently (AR and LT) to establish a relevant pool of evi-
dence for further evaluation. Full-texts from all abstracts
identified for further evaluation and were double-screened
independently by the two reviewers to assess whether they
met the defined inclusion and exclusion criteria. In the
event of a disagreement, the senior investigator (JFD) deter-
mined final inclusion. The lead author contacted confer-
ence abstract authors to attempt to obtain further study
results if available. Studies published from identified confer-
ence abstracts were screened for review.
Data collection process and data items collected
Data from studies included for analysis were extracted by
the lead author (AR) using a standardised data extraction
form (Microsoft Excel 2010 Redmond, WA, USA). A sec-
ond reviewer (ER) also independently assessed the ex-
tracted data, and disagreements were resolved by
discussion until consensus was reached. The following
variables were documented: first author, title, publication
year, study design, study location, setting, intervention de-
scription, comparator description, sample size outcome
description and number of participants achieving SVR12
(and percentage if applicable).
Risk of bias assessment in individual studies
The risk of bias in individual studies was assessed by two re-
viewers (AR and ER) using the Cochrane Collaboration’s risk
of bias tool for randomised studies [18] and the “Newcastle-
Ottawa Scale (NOS) for assessing the quality of nonrando-
mised studies in meta-analyses” [19]. For randomised studies,
these outcomes were evaluated along the six domains: selec-
tion bias, performance bias, detection bias, attrition bias,
reporting bias, and other bias. The domains deemed as ‘high
risk’ of bias for each study per outcome were determined.
Outcomes for the non-randomised studies were evaluated
along seven domains: bias due to confounding; bias in selec-
tion of participants into study; bias in classification of inter-
ventions; bias due to deviations from intended interventions;
bias due to missing data; bias in measurement of outcomes;
and bias in selection of the reported result. The overall risk
of bias for these studies was classified into five categories:
low risk of bias; moderate risk of bias; serious risk of bias;
critical risk of bias or no information.
The NOS scale measures three items: selection of
cases and controls including their definition and repre-
sentativeness; comparability of cases and controls in de-
sign and analysis; and exposure ascertainment. The scale
has a minimum score of 0 and a maximum score of 9.
Risk of bias was rated as high, medium or low according
to the scores obtained by reviewing the selection, com-
parator and exposure categories. Risk of bias was rated
low if studies scored 8 or 9; medium risk if studies were
scored as 6 or 7. Studies were rated as having a high risk
of bias if they were scored as having 5 or less or scored
zero for the comparator category [20].
We assessed the strength of evidence using GRADE
[21]. The scheme evaluates a required group of domains
(study limitations, directness, consistency, precision and
reporting bias) and enables grading of the strength of
evidence as High; Moderate; Low or Insufficient. Use of
this approach enabled us to summarise the outcomes
and findings and make clear judgements about the ef-
fects of the interventions.
Data analysis
The characteristics and findings of the studies included
were summarised and structured using tables. Studies
evaluating similar service environments in community
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and primary care-settings were grouped together to fa-
cilitate comparison.
Study designs, participants, interventions and reported
outcomes varied significantly, and a meta-analysis was
unable to be performed on all included studies. Studies
were excluded from the meta-analysis if the reviewers
considered them to be sufficiently flawed so as not to
contribute meaningfully to the body of evidence [21].
The characteristics and findings of included studies
amenable to meta-analysis were summarised using tables
and forest plots. Risk ratio (RR) and corresponding 95%
confidence interval (95% CI) was calculated for each study
outcome, using the initial number of eligible participants
included and the number achieving the outcome of inter-
est in each arm. Analyses were conducted using statistical
package Stata v14.0 (College Station, TX, USA).
Data synthesis
Deriving pooled estimates of treatment uptake, treatment
completion and SVR
Treatment uptake, treatment completion and SVR and
their exact 95% confidence intervals (CIs) were calcu-
lated assuming a binomial distribution. Pooled estimates
were derived using random- or fixed-effects methods,
according to whether significant heterogeneity (defined
as I2 > 30%) was or was not present, respectively. Sensi-
tivity analysis was used to assess the impact of study
quality (restricting to studies with an NOS score ≥ 6) on
the pooled estimate of SVR.
Further sensitivity analysis was used to assess the impact
of conference abstracts on the pooled estimate of SVR. We
identified studies using similar environments from which to
deliver care and grouped them into categories. Factors iden-
tified as linking studies within categories were examined as
well as factors that differentiated studies from each other.
Results
Study selection
The searches yielded 9137 publications after removal of
duplicates (Fig. 1). This resulted in 121 articles retrieved
for full text inspection and 17 included for analysis. Ex-
planations for exclusion of studies at the full text stage
are provided in Fig. 1. These included: did not fulfil in-
clusion criteria; no treatment intervention; review or
opinion article; other (e.g. insufficient detail reported in
conference abstract).
Study characteristics
Studies evaluated care pathways in primary care [22–28];
in integrated health systems (Extension for Community
Healthcare Outcomes, ECHO) [29–32]; in opioid treat-
ment centres [33–35]; in pharmacies/pharmacist clinics
[36, 37] and by telemedicine [38]. Characteristics and
findings of included studies are set out in Table 2. These
studies originated from United States of America (8);
Australia (5); United Kingdom (2); and Canada (2). The
number of identified studies published as conference ab-
stracts reflected the length of time that DAAs have been
widely available outside specialist environments. Six
from seventeen studies were only available as conference
abstracts. There were two randomised controlled trials,
four cohort studies, nine retrospective data analyses and
two prospective non-experimental designs. All were con-
ducted on populations at high risk of HCV infection,
such as people who inject drugs and people on Opioid
Substitution Therapy (OST) programmes. Table 3 de-
scribes the outcomes from the meta-analysis of selected
studies and Table 4 defines the Strength of Evidence As-
sessment for identified studies answering the PRISMA
objective. Details of assessment of bias and design for
studies are located in Additional file 2 (non-randomised)
and Additional file 3 (randomised)).
Primary care
Seven studies evaluated interventions to enhance treat-
ment uptake and achievement of SVR in primary care
environments [22–28]. One study was a randomised
controlled trial (RCT), two were cohort studies and four
were non-randomised studies. Four studies utilised
nurses in delivery of the care pathway. Three studies in-
cluded uptake of testing and assessment in their descrip-
tion of care and all the studies discussed uptake of
treatment and ascertainment of SVR. The RCT reported
a significant difference between those commencing
treatment in primary care arm than in the Standard of
Care arm (SOC) (75% Vs 34%, p < 0.001) and proportion
gaining an SVR12 was significantly higher in the primary
care arm than in the SOC arm (49% vs 34%, p = 0.043).
Two studies reported a reduction in potential SVR
rates because of failure of participants to complete the
confirmatory blood test at 12 weeks after completion of
DAA treatment. All studies reported increased access to
treatment in primary care environments and high rates
of SVR attainment.
Integrated health systems (ECHO)
Four studies provided evaluations of care through in-
tegration of specialist centres with primary care deliv-
ery [29–32]. One study was a retrospective cohort
study and three were non-randomised studies. Three
of the four studies utilised the “ECHO” care pathway
in which hepatitis specialists support primary care
providers through video-conferencing and collabor-
ation on specific cases, with a defined curriculum and
active mentorship [39]. None of the studies discussed
uptake of testing amongst their treated cohorts. All
studies increased access to treatment and high rates
of attainment of SVR.
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Opioid treatment Centres
Three studies evaluated care provision in dedicated set-
ting where people with opioid addiction received harm
reduction and treatment services [33–35]. All three stud-
ies were non-randomised analyses of treatment data and
assessed the uptake and completion of treatment by par-
ticipants using these services. No assessment of the ex-
tent of testing of these populations was discussed. All
studies reported high rates of treatment uptake and
treatment completion in diagnosed individuals. These
studies all described problems with retention of partici-
pants in the service post-treatment with consequent re-
ductions in uptake of confirmatory SVR testing.
Pharmacies / pharmacist clinics
Two studies evaluated hepatitis C care provision by phar-
macists in community and primary care settings [36, 37].
One study was a feasibility RCT that compared the delivery
of a community pharmacy test and treatment pathway with
standard hospital-based care. One study was a non-
randomised data analysis. The RCT demonstrated an in-
crease in testing uptake, when the participant received all
care in a pharmacy environment and showed increased re-
tention in care. Data from this study also demonstrates a
marked loss of patients from the care pathway when they
were asked to attend the local hospital. The non-randomised
study concluded that patients treated in pharmacist clinics
achieve high rates of SVR similar to non-pharmacist clinics.
Telemedicine
A single cohort database study [38] compared treatment up-
take and SVR rates in participants cared for through a tele-
medicine pathway (n= 157) with participants cared for
through a standard care pathway (n= 1130). The study
Fig. 1 Flow diagram of search results
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demonstrated increased access to care form under-served
and remote areas and concluded that the telemedicine inter-
vention achieved high rates of treatment initiation and SVR.
Data synthesis
The 12 studies eligible for meta-analysis examined treat-
ment uptake, completion and SVR in a variety of primary
care environments; integrated systems (ECHO) that linked
specialists with primary care providers; opioid treatment
centres; pharmacies / pharmacist clinics; telemedicine and
specialist hospital care. The remaining five studies were
unsuitable for meta-analysis due to non-reporting of the
required outcomes, use of Pegylated interferon or insuffi-
cient time to achieve SVR. Across the 12 studies, the
pooled estimate is shown in Additional file 4 Table S3.
Forest plots for suitable studies are set out in Figs. 2, Fig. 3
and Fig. 4. These plots demonstrate that across the variety
of community and primary care environments, a consist-
ent direction of effect to improve treatment uptake, treat-
ment completion and achievement of SVR is seen. Greater
uptake was seen for the Primary Care and Pharmacy Loca-
tions, compared to the Specialist Care Location and com-
parable SVR rates were demonstrated (Table 2).
In this analysis, heterogeneity was noted to be high so
a sensitivity analysis restricting to higher-quality studies
(NOS score ≥ 6) was performed. Despite this the hetero-
geneity remained high. A further sensitivity analysis was
performed restricting the meta-analysis to published
studies only. See Additional file 3 in the appendix. This
had no impact on heterogeneity.
Discussion
This paper reviews evaluations of care pathways that
utilise DAAs in a range of community and primary care
settings. The WHO Guidelines on care and treatment of
persons diagnosed with chronic HCV infection promote
simplified service delivery models; integration with other
services; decentralised services supported by task-sharing;
and community engagement to address stigma and increase
reach [14]. The studies considered in this systematic review
Table 4 Summary of key findings, outcomes and strength of evidence
Outcome Study designs/
No. Studies
Findings and Direction of Effect GRAD E[21]
1. Uptake of HCV treatment RCT – 2
Cohort – 3
Observational – 5
Two RCTs assessed as having low risk of bias
reported a positive effect on uptake with precision
and a consistent positive direction of effect. One
cohort study assessed as having medium-grade
study limitations also reported a positive
effect on uptake.
Medium
2. Completion of Treatment Cohort - 1
Observational - 2
One cohort study with medium study limitations
reported a positive direction of effect on uptake.
Low
3. Sustained Viral Response at 12 weeks (%)(SVR12) RCT −2
Cohort - 4
Observational - 11
Two RCTs assessed as having low risk of bias
reported a positive effect on SVR but were imprecise
in the estimate of effect size. Four cohort studies and
11 observational studies with over 10,000 participants
all reported a consistent positive direction of effect,
but with significant study limitations.
Medium
Table 3 Meta-analysis of studies examining treatment uptake, treatment completion and SVR among people with Hepatitis C
treated in a variety of community settings or specialist hospital care
Inclusion Criteria Treatment Uptake Treatment Completion SVR
No. Of
studies
Heterogeneity
(I2)
Pooled estimate
(95% CI)
No. Of
studies
Heterogeneity
(I2)
Pooled estimate
(95% CI)
No. Of
studies
Heterogeneity
(I2)
Pooled estimate
(95% CI)
Opioid Treatment
Centres
2 77.7% 91.9 (82.2–100) 3 0.0% 82.3 (77.8–86.8)
Integrated Health
System (ECHO)
1 Not
applicable
75.6 (68.0–83.2) 1 Not
applicable
96.8 (93.2–100) 2 84.6% 81.3 (66.9–95.5)
Telemedicine 1 Not
applicable
22.3 (15.8–28.8) 1 Not
applicable
51.4 (34.8–68.0)
Primary Care 1 Not
applicable
67.4 (53.9–80.9) 1 Not
applicable
100 (97.95–100) 5 94.9% 74.4 (60.3–88.5)
Pharmacies /
Pharmacist Clinics
1 Not
applicable
66.67 (58.3–75.1) 2 89.0% 79.0 (79.2–98.9)
Specialist Care 2 0.0% 34.5 (31.79–37.29) 5 96.8% 73.46 (60.9–85.9)
Abbreviations: CI, Confidence interval; SVR, Sustained virologic response
a. Random-effects method used if I2 ≥ 30%
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Fig. 3 Forest plots of completed treatment and SVR rates for selected studies in Opioid Treatment Centres Location
Fig. 2 Forest plots of treatment uptake, completed treatment and SVR rates for selected studies in the Primary Care Location
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and meta-analysis therefore provide some evidence for the
extent of implementation of these guidelines.
The studies identified that met our inclusion criteria were
grouped according to location: primary care; integrated
health care systems (ECHO); opioid treatment centres; in
pharmacies / pharmacist clinics; and through telemedicine.
These care pathways acknowledged the need to provide
local services with reach into the communities where
people with hepatitis C live their lives.
In all three areas assessed in our study: uptake of treat-
ment; completion of treatment; and attainment of SVR, a
positive outcome was reported by all identified studies. This
was seen across each of the distinct environments from
which the care was provided. Since the positive outcomes
were drawn from distinctly different pathways of care, fur-
ther confidence might be inferred from this consistency of
direction of effect. However, amongst the studies that met
our inclusion criteria, there was a lack of studies using com-
parators from specialist centres. Data contained in these
studies nevertheless demonstrated high uptake of treatment
and high rates of attainment of SVR: among populations of
vulnerable people who normally struggle to access care.
Studies that did include comparators showed no significant
differences in uptake or SVR. Several of the studies re-
ported an increased uptake of treatment, but most reported
equivalence. Some studies reported lower rates of attain-
ment of SVR, because of study participants failing to
undergo a confirmatory blood test post-treatment, within
the study timelines. With DAAs SVR rates of greater than
97% are delivered if patients adhere to treatment, therefore
completion of therapy can be a surrogate for SVR [16].
Previous systematic reviews have considered barriers
and facilitators to care, as well as the views and experi-
ences of people who inject drugs [7, 40]. These studies
concluded that the target groups for HCV often had
poor levels of knowledge about the infection and of the
processes involved with testing and treatment. A fear of
stigma and discrimination and a reticence to discuss risk
behaviours tended to prevent engagement. These bar-
riers could be addressed through educating participants,
increasing awareness and redress of institutionalised
stigma and integrating HCV treatment pathways into
other services where the target group were likely to go.
Increased uptake of testing has been observed when
testing is offered at the same time as other routine care
[4]; with integrated services for both opioid users and
with mental health services. There are advantages to tar-
geting services at populations with predicted high preva-
lence of HCV [41]. Provision of HCV treatment as part
of a directly observed treatment arrangement, increased
attainment of SVR [42]. Achievement of these factors
within local health systems needs to be commonplace if
the WHO target for elimination is to be met [43]. There
is some evidence that this is now happening [44].
The results from this systematic review highlight the
lack of well-controlled randomised controlled trials and
Fig. 4 Forest plots of treatment uptake and SVR rates for studies in the Pharmacy / Pharmacist Clinic Location
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comparative studies, with just two randomised con-
trolled trials identified and four cohort studies. While
the publication of such studies is an important step in
building confidence that decentralisation of hepatitis C
treatment can be accomplished, the paucity of evidence
reflects the difficulty in funding pathways to care studies
and the relatively recent removal of the restrictions on
the use of DAAs. Two further studies have been com-
menced identify that further evaluations of interferon-
free treatments in primary care environments are under-
way [45, 46].
As with most systematic reviews, the quality of the
studies and the heterogeneity of the study populations
included in the analysis present a limitation of this
study. The sensitivity analyses performed for our ana-
lysis did not have an impact on heterogeneity, mean-
ing that an unexplained source of heterogeneity may
be present. These difficulties may reflect the variety
of ways in which patients can access HCV treatment.
This may be positive and may be explained by the
development of more patient centred pathways. These
factors prevented a meta-analysis being achieved for
many of the studies identified as eligible through the
PICOS question defined for this review. Many of the
studies that met the inclusion criteria were only avail-
able as conference abstracts at the time of review, in-
cluding one of the randomised controlled trials.
Nevertheless, over 10,000 participants were included
in the identified studies. All studies had a consistent
direction of effect, providing optimism that future
evaluations will confirm with precision the effect size
that should be delivered by simplifying treatment
pathways and decentralising them to primary care. In
terms of further limitations, we acknowledge limita-
tions in the chosen methods for the systematic re-
view, including potential publication bias to the
findings by excluding non-English language studies; or
any other biases introduced by our chosen inclusion
and exclusion criteria.
Conclusion
This systematic review and meta-analysis identified stud-
ies which demonstrate the feasibility of decentralising
care and providing local services with reach into com-
munities of people infected with HCV. Such pathways
may increase uptake of treatment and can provide sus-
tained viral responses equivalent to those attained in
specialist centres. Further studies are needed to confirm
the promising start to the implementation of interferon-
free treatment regimens. The successful implementation
of such pathways to deliver successful patient outcomes
is a key requirement for a “treatment as prevention”
strategy as a pathway to elimination of HCV [47].
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